Document:

Amendment No. 2 to the Celgene Corporation 2008 Stock Incentive Plan

 Exhibit 10.1 
 AMENDMENT NO. 2 
 TO THE 

CELGENE CORPORATION 
 2008 STOCK INCENTIVE PLAN 
 (AMENDED AND RESTATED AS OF JUNE 17, 2009)

 WHEREAS, Celgene Corporation (the “Company”) maintains the Celgene Corporation 2008 Stock
Incentive Plan (Amended and Restated as of June 17, 2009) (the “Plan”); 
 WHEREAS, pursuant to
Article 14 of the Plan, the Board of Directors of the Company (the “Board”) may at any time, and from time to time, amend, in whole or in part, any or all of the provisions of the Plan, subject to stockholder approval in certain
instances; and 
 WHEREAS, the Board desires to amend the Plan, effective on the date of the Company’s annual
meeting of stockholders occurring in 2012 (the “2012 Annual Meeting”), subject to stockholder approval at the 2012 Annual Meeting. 
 NOW, THEREFORE, the Board takes the following action with regard to the Plan: 
 I. Pursuant to Article 14 of the Plan, the Plan is hereby amended, effective on the 2012 Annual Meeting and subject to stockholder approval at the 2012 Annual Meeting, as follows: 

1. The first and second sentences of Section 4.1(a) of the Plan are amended in their entirety to read as follows:

 “The aggregate number of shares of Common Stock which may be issued or used for reference purposes under
this Plan or with respect to which all Awards may be granted shall not exceed 95,981,641 shares (subject to any increase or decrease pursuant to Section 4.2). Any shares of Common Stock that are subject to Restricted Stock Awards or Other
Stock-Based Awards or Performance-Based Awards denominated in shares of Common Stock granted on or after the date of the Company’s annual meeting of stockholders occurring in 2012, shall be counted against this limit as 2.1 shares for every
share granted.” 
 2. The fourth sentence of Section 4.1(a) of the Plan is amended in its entirety to
read as follows: 
 “If a share of Restricted Stock or an Other Stock-Based Award or a Performance-Based
Award denominated in shares of Common Stock granted under this Plan is forfeited for any reason on or after the date of the Company’s annual meeting of stockholders occurring in 2012, 2.1 shares of Common Stock shall again be available for the
purposes of Awards under the Plan.” 
 3. Article 18 of the Plan is amended in its entirety to read as
follows: 
 “Article 18. 
 TERM OF PLAN 
 No Award shall be granted pursuant to the Plan on or after
April 18, 2022, but Awards granted prior to such date may, and the Committee’s authority to administer the terms of such Awards shall, extend beyond that date; provided, however, that no Award (other than a Stock Option or Stock
Appreciation Right) that is intended to be “performance-based” under Section 162(m) of the Code shall be granted on or after the first meeting of the stockholders in the fifth year following the year in which the stockholders approve
the Performance Goals set forth on Exhibit A unless the Performance Goals set forth on Exhibit A are reapproved (or other designated performance goals are approved) by the stockholders no later than the first stockholder meeting that occurs in the
fifth year following the year in which stockholders approve the Performance Goals set forth on Exhibit A.” 
 II. Except as
specifically amended hereby, the Plan is hereby ratified and confirmed in all respects and remains in full force and effect.Joinder Agreement

 Exhibit 10.1 
 EXECUTION VERSION 
 JOINDER AGREEMENT 

This Joinder Agreement is dated as of June 14, 2012 (this “Agreement”), by and among each of the financial
institutions set forth on Schedule A annexed hereto (each a “New Term Loan Lender” and collectively the “New Term Loan Lenders”), Valeant Pharmaceuticals International, Inc., a corporation continued under the
federal laws of Canada (“Borrower”), the undersigned subsidiaries of Borrower and Goldman Sachs Lending Partners LLC (“GSLP”), as Administrative Agent and Collateral Agent. 

RECITALS: 

WHEREAS, reference is hereby made to the Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13,
2012, as amended by Amendment No. 1, dated as of March 6, 2012 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the “Credit Agreement”; the terms defined therein and not
otherwise defined herein being used herein as therein defined), among Borrower, certain Subsidiaries of Borrower, as Guarantors, the Lenders party thereto from time to time, GSLP, J.P. Morgan Securities LLC and Morgan Stanley Senior Funding, Inc.
(“Morgan Stanley”), as Joint Lead Arrangers and Joint Bookrunners, JPMorgan Chase Bank, N.A. (“JPMorgan”) and Morgan Stanley, as Co-Syndication Agents, JPMorgan, as Issuing Bank, GSLP, as Administrative Agent and
Collateral Agent, and the other Agents party thereto; 
 WHEREAS, subject to the terms and conditions of the Credit
Agreement, Borrower may obtain New Revolving Loan Commitments and/or New Term Loan Commitments by entering into one or more Joinder Agreements with the New Term Loan Lenders; and 

WHEREAS, pursuant to Section 2.25 of the Credit Agreement, the Credit Agreement may, without the consent of any other
Lenders, be amended as may be necessary or appropriate, in the opinion of the Administrative Agent, to give effect to the provisions of Section 2.25 of the Credit Agreement. 

NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto
agree as follows: 
 Each New Term Loan Lender (i) confirms that it has received a copy of the Credit Agreement and the
other Credit Documents, together with copies of the financial statements referred to therein and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement;
(ii) agrees that it will, independently and without reliance upon the Administrative Agent or any other Lender or Agent and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit
decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes Administrative Agent and each other Agent to take such action as agent on its behalf and to exercise such powers under the Credit Agreement and
the other Credit Documents as are delegated to Administrative Agent or such other Agent, as the case may be, by the terms thereof, together with such powers as are reasonably incidental thereto; and (iv) agrees that it will perform in
accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender. 
 Each New Term Loan Lender hereby commits to provide its respective New Term Loan Commitment as set forth on Schedule A annexed hereto, on the terms and subject to the conditions set forth below:

	1.	Applicable Margin. The Applicable Margin for each New Term Loan made pursuant to this Agreement (each a “Series A Tranche B Term Loan”) shall
mean, as of any date of determination, (A) with respect to Series A Tranche B Term Loans that are Eurodollar Loans, 3.75% per annum, and (B) with respect to Series A Tranche B Term Loans that are Base Rate Loans, 2.75% per annum.

  

	2.	Principal Payments. Borrower shall make principal payments on the Series A Tranche B Term Loans in installments on the dates and in the amounts equal to the
percentage set forth below of an amount equal to the aggregate principal amount of the Series A Tranche B Term Loans outstanding as of the date hereof: 

  

			
	 Amortization Date
	  	Series A Tranche B Term
Loan
Installments
	 September 30, 2012
	  	0.25%
	 December 31, 2012
	  	0.25%
	 March 31, 2013
	  	0.25%
	 June 30, 2013
	  	0.25%
	 September 30, 2013
	  	0.25%
	 December 31, 2013
	  	0.25%
	 March 31, 2014
	  	0.25%
	 June 30, 2014
	  	0.25%
	 September 30, 2014
	  	0.25%
	 December 31, 2014
	  	0.25%
	 March 31, 2015
	  	0.25%
	 June 30, 2015
	  	0.25%
	 September 30, 2015
	  	0.25%
	 December 31, 2015
	  	0.25%
	 March 31, 2016
	  	0.25%
	 June 30, 2016
	  	0.25%
	 September 30, 2016
	  	0.25%
	 December 31, 2016
	  	0.25%
	 March 31, 2017
	  	0.25%
	 June 30, 2017
	  	0.25%
	 September 30, 2017
	  	0.25%
	 December 31, 2017
	  	0.25%
	 March 31, 2018
	  	0.25%
	 June 30, 2018
	  	0.25%
	 September 30, 2018
	  	0.25%
	 December 31, 2018
	  	0.25%
	 Tranche B Term Loan Maturity Date
	  	Remaining Balance

  

	3.	Voluntary and Mandatory Prepayments. Scheduled installments of principal of the Series A Tranche B Term Loans set forth above shall be reduced in connection with
any voluntary or mandatory prepayments of the Series A Tranche B Term Loans in accordance with Sections 2.12, 2.13 and 2.14 of the Credit Agreement respectively. 

 

	4.	Closing Fee. Borrower agrees to pay on the date hereof to Administrative Agent, for the account of each New Term Loan Lender party to this Agreement, as fee
compensation for the funding of such New Term Loan Lender’s Series A Tranche B Term Loans, a closing fee in an amount equal to 2.50% of the aggregate principal amount of such New Term Loan Lender’s Series A Tranche B Term Loans funded as
of the date hereof. 

  
 -2-

	5.	Prepayment Premium. In the event that on or prior to the first anniversary of the Series A Tranche B Term Loan Funding Date (as defined below), the Borrower
(x) makes any prepayment of the Series A Tranche B Term Loans in connection with any Repricing Transaction or (y) effects any amendment of the Credit Agreement resulting in a Repricing Transaction, the Borrower shall pay to the
Administrative Agent, for the ratable account of each of the applicable Lenders, (I) in the case of clause (x) above, a prepayment premium of 1% of the amount of the Series A Tranche B Term Loans being prepaid and (II) in the case of
clause (y) above, a payment equal to 1% of the aggregate amount of the applicable Series A Tranche B Term Loans outstanding immediately prior to such amendment. 

 

	    	For purposes of this Agreement, a “Repricing Transaction” means the prepayment or refinancing of all or a portion of the Series A Tranche B Term Loans
with the incurrence by any Credit Party of any long-term bank debt financing having an effective interest cost or weighted average yield (excluding any arrangement or commitment fees in connection therewith) that is less than the effective interest
cost for or weighted average yield of the Series A Tranche B Term Loans, including without limitation, as may be effected through any amendment to this Agreement relating to the effective interest cost for, or weighted average yield of, the Series A
Tranche B Term Loans. 

  

	6.	Proposed Borrowing. In accordance with Section 2.25 of the Credit Agreement, Borrower has previously delivered to Administrative Agent an executed Funding
Notice for Series A Tranche B Term Loans, requesting a proposed borrowing in the principal amount of $600,000,000 (the “Proposed Borrowing”) on the date hereof (the “Series A Tranche B Term Loan Funding Date”). Each
New Term Loan Lender shall make its Series A Tranche B Term Loan available to Administrative Agent not later than 11:00 a.m. (New York City time) on the date hereof, by wire transfer of same day funds in Dollars at the Principal Office designated by
Administrative Agent. Promptly upon receipt thereof, Administrative Agent shall make the proceeds of the Series A Tranche B Term Loans available to Borrower on the date hereof by causing an amount of same day funds in Dollars equal to the proceeds
of all such loans received by Administrative Agent from New Term Loan Lenders to be credited to the account of Borrower, at the Principal Office designated by Administrative Agent or to such other account as may be designated in writing to
Administrative Agent by Borrower. 

  

	7.	New Lenders. Each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the execution of this Agreement, is a “Lender”
under the Credit Agreement) acknowledges and agrees that upon its execution of this Agreement its Series A Tranche B Term Loan Commitments shall be effective and that such New Term Loan Lender shall become a “Lender” under, and for all
purposes of, the Credit Agreement and the other Credit Documents, and shall be subject to and bound by the terms thereof, and shall perform all the obligations of and shall have all rights of a Lender thereunder. 

 

	8.	Amendment to Credit Agreement. Section 1.1 of the Credit Agreement is hereby amended (the “Amendment”) by deleting clause (a) of the
definition of Applicable Margin and replacing it in its entirety with the following: 

 “(a) (i) with respect to Tranche
B Term Loans that are Eurodollar Rate Loans, 3.75% per annum and (ii) with respect to Tranche B Term Loans that are Base Rate Loans, 2.75% per annum”. 

  
 -3-

	    	The Amendment set forth in this Section 8 shall be effective on the Series A Tranche B Term Loan Funding Date, upon receipt by the Administrative Agent of an
executed counterpart of this Agreement by (A) the Borrower, (B) the other Credit Parties and (C) the Administrative Agent and consummation of the Proposed Borrowing. 

 

	9.	Credit Agreement Governs. Series A Tranche B Term Loans shall be subject to the provisions of the Credit Agreement and the other Credit Documents, except
as set forth in this Agreement, and shall constitute Tranche B Term Loans thereunder. For the avoidance of doubt, Section 5 of this Agreement shall supersede the final paragraph of Section 2.13(a) of the Credit Agreement with respect to
Series A Tranche B Term Loans. 

  

	10.	Borrower’s Certifications. By its execution of this Agreement, the undersigned officer, to the best of his or her knowledge, and Borrower hereby certify
that: 

  

	 	i.	The representations and warranties contained in the Credit Agreement and the other Credit Documents are true and correct in all material respects on and as of the date
hereof to the same extent as though made on and as of the date hereof, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties were true and correct in all
material respects on and as of such earlier date; 

  

	 	ii.	No event has occurred and is continuing or would result from the consummation of the Proposed Borrowing contemplated hereby that would constitute a Default or an Event
of Default; and 

  

	 	iii.	Borrower has performed in all material respects all agreements and satisfied all conditions which the Credit Agreement provides shall be performed or satisfied by it on
or before the date hereof in connection with the Proposed Borrowing. 

  

	11.	Borrower Covenants. By its execution of this Agreement, Borrower hereby covenants that: 

 

	 	i.	Borrower shall deliver or cause to be delivered the following legal opinions and documents: originally executed copies of the favorable written opinions of
(a) Skadden, Arps, Slate, Meagher & Flom LLP, U.S. counsel to the Credit Parties, (b) Chancery Chambers, special Barbados counsel to the Credit Parties, (c) Norton Rose OR LLP, special Canadian counsel to the Credit Parties
and (d) Baker & McKenzie, special Luxembourg counsel to the Credit Parties, together with all other legal opinions and other documents reasonably requested by Administrative Agent in connection with this Agreement; and

  

	 	ii.	Set forth on the attached Officers’ Certificate are the calculations (in reasonable detail) demonstrating compliance, on a Pro Forma Basis after giving effect to
the New Term Loans and the application of the proceeds thereof, with the financial tests described in Section 6.7 of the Credit Agreement as of the last day of the most recently ended Fiscal Quarter after giving effect to such New Term Loan
Commitments. 

  

	12.	Eligible Assignee. By its execution of this Agreement, each New Term Loan Lender (other than any New Term Loan Lender that, immediately prior to the
execution of this Agreement, is a “Lender” under the Credit Agreement) represents and warrants that it is an Eligible Assignee. 

  
 -4-

	13.	Notice. For purposes of the Credit Agreement, the initial notice address of each New Term Loan Lender shall be as set forth below its signature below.

  

	14.	Non-U.S. Lenders. For each New Term Loan Lender that is a Non-U.S. Lender, delivered herewith to Administrative Agent are such forms, certificates or other
evidence with respect to United States federal income tax withholding matters as such New Term Loan Lender may be required to deliver to Administrative Agent pursuant to subsection 2.20(d) of the Credit Agreement. 

 

	15.	Recordation of the New Loans. Upon execution and delivery hereof, Administrative Agent will record the Series A Tranche B Term Loans made by New Term Loan
Lenders pursuant hereto in the Register. 

  

	16.	Reaffirmation. 

  

	 	i.	Each Credit Party hereby expressly acknowledges the terms of this Agreement and reaffirms, as of the date hereof, the covenants and agreements contained in each Credit
Document to which it is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this Agreement and the transactions contemplated hereby. 

 

	 	ii.	Each Credit Party, by its signature below, hereby affirms and confirms (a) its obligations under each of the Credit Documents to which it is a party, and
(b) the pledge of and/or grant of a security interest or hypothec in its assets as Collateral to secure such Obligations, all as provided in the Collateral Documents as originally executed, and acknowledges and agrees that such guarantee,
pledge and/or grant continue in full force and effect in respect of, and to secure, such Obligations under the Credit Agreement and the other Credit Documents. 

 

	 	ii.	Each Credit Party acknowledges and agrees that each of the Credit Documents in existence as of the date hereof shall be henceforth read and construed in accordance with
and so as to give full force and effect to the ratifications, confirmations, acknowledgements and agreements made herein. 

  

	17.	Amendment, Modification and Waiver. This Agreement may not be amended, modified or waived except by an instrument or instruments in writing signed and delivered
on behalf of each of the parties hereto. 

  

	18.	Entire Agreement. This Agreement, the Credit Agreement and the other Credit Documents constitute the entire agreement among the parties with respect to the
subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties or any of them with respect to the subject matter hereof. It is understood and agreed that each reference in
each Credit Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended and supplemented hereby and that this Agreement is a Credit Document. 

 

	19.	GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEW YORK. 

  
 -5-

	20.	Severability. Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the
extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any
other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as would be enforceable. 

 

	21.	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same
agreement. 

 [Remainder of page intentionally left blank] 

  
 -6-

 IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer
to execute and deliver this Agreement as of the date first written above. 
  

			
	GOLDMAN SACHS LENDING PARTNERS LLC, as a “New Term Loan Lender”
		
	By:	 	/s/ Robert Ehudin
		 	Authorized Signatory

  

			
	Notice Address:	 	Goldman Sachs & Co.
		 	30, Hudson Street, 5th Floor
		 	Jersey City, NJ 07302
		
		 	Robert Ehudin
		 	Authorized Signatory
		
	Attention:	 	Michelle Latzoni
	Telephone:	 	212-934-3921
	Facsimile:	 	646-769-7700

  
 S-1

 
					
	VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.
	as Borrower
		
	By:	 	/s/ Howard Schiller
		 	Name:	 	Howard Schiller
		 	Title:	 	Executive Vice President & Chief
		 		 	Financial Officer
	
	VALEANT PHARMACEUTICALS INTERNATIONAL
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President & Chief Operating Officer
	
	ATON PHARMA, INC.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President & Chief Operating Officer
	
	CORIA LABORATORIES, LTD.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President & Chief Operating Officer
	
	DOW PHARMACEUTICAL SCIENCES, INC.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President & Chief Operating Officer

  
 S-2

 
					
	VALEANT PHARMACEUTICALS
NORTH AMERICA LLC
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	DR. LEWINN’S PRIVATE FORMULA INTERNATIONAL, INC.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	OCEANSIDE PHARMACEUTICALS, INC.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	PRINCETON PHARMA HOLDINGS, LLC
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	PRIVATE FORMULA CORP.
	as Guarantor
		
	By:	 	/s/ Rajiv De Silva
		 	Name:	 	Rajiv De Silva
		 	Title:	 	President

  
 S-3

 
					
	RENAUD SKIN CARE LABORATORIES, INC.
	 as Guarantor

		
	 By:
	 	 /s/ Rajiv De Silva

		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	 VALEANT BIOMEDICALS, INC.

	 as Guarantor

		
	 By:
	 	 /s/ Rajiv De Silva

		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	 BIOVAIL AMERICAS CORP.

	 as Guarantor

		
	 By:
	 	 /s/ Rajiv De Silva

		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	 PRESTWICK PHARMACEUTICALS, INC.

	 as Guarantor

		
	 By:
	 	 /s/ Rajiv De Silva

		 	Name:	 	Rajiv De Silva
		 	Title:	 	President
	
	VALEANT HOLDINGS (BARBADOS) SRL
	 as Guarantor

		
	 By:
	 	 /s/ Richard K. Masterson

		 	Name:	 	Richard K. Masterson
		 	Title:	 	President & COO
	
	VALEANT INTERNATIONAL (BARBADOS) SRL
	 as Guarantor

		
	 By:
	 	 /s/ Richard K. Masterson

		 	Name:	 	Richard K. Masterson
		 	Title:	 	President & COO

  
 S-4

					
	BIOVAIL LABORATORIES INTERNATIONAL
(BARBADOS) SRL
	 as Guarantor

		
	 By:
	 	 /s/ Richard K. Masterson

		 	 Name:
	 	Richard K. Masterson
		 	Title:	 	President & COO
	
	 HYTHE PROPERTY INCORPORATED

	 as Guarantor

		
	 By:
	 	 /s/ Richard K. Masterson

		 	Name:	 	Richard K. Masterson
		 	Title:	 	President & COO
	
	 VALEANT CANADA GP LIMITED

	 as Guarantor

		
	 By:
	 	 /s/ Robert R. Chai-Onn

		 	Name:	 	Robert R. Chai-Onn
		 	Title:	 	Vice President
	
	 VALEANT CANADA LP by its sole general partner,

VALEANT CANADA GP LIMITED

	 as Guarantor

		
	 By:
	 	 /s/ Robert R. Chai-Onn

		 	Name:	 	Robert R. Chai-Onn
		 	Title:	 	Director
	
	 V-BAC HOLDING CORP.

	 as Guarantor

		
	 By:
	 	 /s/ Robert R. Chai-Onn .

		 	Name:	 	Robert R. Chai-Onn
		 	Title:	 	Vice President

  
 S-5

 
			
	 BIOVAIL INTERNATIONAL, S.À R.L.
 as Guarantor

		
	By:	 	/s/ Kuy Ly ANG
		 	Name:     Kuy Ly ANG
		 	Title:       Manager
	
	PHARMASWISS SA
	as Guarantor
		
	By:	 	/s/ Matthias Courvoisier
		 	Name:     Matthias Courvoisier
		 	Title:       Chairman of the Board

  

					
	Signed by	 		 	
	 Valeant Holdco 2 Pty Ltd (ACN 154 341 367)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Rajiv De Silva

	Signature of director	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Rajiv De Silva

	Name of director (please print)	 		 	Name of director (please print)

  
 S-6

					
	Signed by	 		 	
	 Wirra Holdings Pty Limited (ACN 122 216 577)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Howard B. Schiller

	 Signature of director
	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Howard B. Schiller

	 Name of director (please print)
	 		 	Name of director (please print)
			
	Signed by	 		 	
	 Wirra Operations Pty Limited (ACN 122 250 088)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Howard B. Schiller

	 Signature of director
	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Howard B. Schiller

	 Name of director (please print)
	 		 	Name of director (please print)
			
	Signed by	 		 	
	 iNova Pharmaceuticals (Australia) Pty Limited (ACN 000 222 408)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Howard B. Schiller

	 Signature of director
	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Howard B. Schiller

	 Name of director (please print)
	 		 	Name of director (please print)

  
 S-7

					
	Signed by	 		 	
	 iNova Sub Pty Limited (ACN 134 398 815)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Howard B. Schiller

	 Signature of director
	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Howard B. Schiller

	 Name of director (please print)
	 		 	Name of director (please print)
			
	Signed by	 		 	
	 Wirra IP Pty Limited (ACN 122 536 350)
 as Guarantor
 in accordance with section 127 of the Corporations Act 2001 by two
directors:
	 		 	
			
	/s/ Robert Chai-Onn	 		 	 /s/ Howard B. Schiller

	 Signature of director
	 		 	Signature of director
			
	Robert Chai-Onn	 		 	 Howard B. Schiller

	 Name of director (please print)
	 		 	Name of director (please print)

  
 S-8

			
	Consented to by:
	
	 GOLDMAN SACHS LENDING PARTNERS LLC
 As Administrative Agent and Collateral Agent

		
	By:	 	/s/ Robert Ehudin
		 	Authorized Signatory

  
 S-9

 SCHEDULE A 
 TO JOINDER AGREEMENT 
  

									
	 Name of Lender
	  	 Type of Commitment
	  	 	  	Amount	 
	GOLDMAN SACHS LENDING PARTNERS LLC	  	Series A Tranche B Term Loan Commitment	  		  	$	600,000,000.00	  
		  		  		  	  
	  
	 
		  		  	Total:	  	$	600,000,000.00

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]